Colgate-Palmolive reports Q1 2026 results on Thursday with the Street freshly lined up behind it — but the stock's 2% slide on Monday signals investors are less certain.
The analyst backdrop is notably constructive heading into the print. JP Morgan and UBS both raised price targets on Monday, with UBS lifting to $100 and JP Morgan nudging to $96. RBC Capital reiterated its Outperform at $102. All three moves came the same day the stock fell to $85.37. Earlier in the week, Morgan Stanley trimmed its target from $100 to $95 while keeping Overweight, and Barclays cut more aggressively to $79. The net message from the Street: most major firms still see meaningful upside, but valuation sensitivity is rising. The consensus mean target sits at $96, implying roughly 12% return potential from current levels. The analyst recommendation differential ranks in the 92nd percentile of the universe — a signal that CL's relative analyst positioning is unusually positive.
Bulls point to Colgate's global reach — around 70% of sales come from international markets — and a multi-year step-up in advertising spend from 11.6% of sales in 2021 to 13.5% in 2024 as evidence of durable brand investment. Bears are focused on margin pressure: gross margin fell 75 basis points year-over-year in Q2 2025, and volume trends turned negative in both Q1 and Q2 2025 despite price growth. The Hill's pet food segment remains a specific drag, with measured retail channel declines worsening through the back half of 2025. The 12-month forward EPS growth estimate ranks in the 75th percentile, suggesting the market expects the margin headwinds to ease — but EPS surprise history is weak, ranking just in the 9th percentile.
Short interest tells a relaxed story. At 2.4% of free float, bearish positioning is modest and declining — down more than 8% on the week and around 4% over the past month. Borrow costs have eased sharply, running at just 0.29% after a week-on-week drop of over 40%. Availability is extremely loose; lending market pressure is essentially absent. Options positioning is similarly calm: the put/call ratio at 1.13 is slightly below its 20-day average of 1.18, a mild negative z-score that points to no unusual hedging activity ahead of the release. The ORTEX short score of 33 is low and has been drifting down from 35.6 at the April 20 peak, consistent with the broad retreat in short positioning. Closest peer Clorox was the notable outlier on the day, falling nearly 10% — a reminder that the consumer staples print cycle can deliver sharp reactions even when positioning is light.
Thursday's release will test whether Colgate's volume trajectory is recovering and whether pricing power is holding up against raw material costs — the two variables that divided bulls and bears most sharply through 2025.
See the live data behind this article on ORTEX.
Open CL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
